The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors
Sung Hee Lim(Samsung Medical Center), Jeeyun Lee(Samsung Medical Center)
Cited by 24
Related Papers
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|614
Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline)
|Journal of the Korean Gastric Cancer Association|2025|96
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study
|Seoul National University Open Repository (Seoul National University)|2021|95
ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC).
|Journal of Clinical Oncology|2019|79
Gastrointestinal malignancies harbor actionable MET exon 14 deletions
|Oncotarget|2015|61